Blog
RSS FeedPosted by Michael Wonder on 15 Sep 2021
Health Canada approves Lumakras (sotorasib), the first and only targeted treatment for patients with KRAS G12C mutated locally advanced or metastatic non--small cell lung cancer
14 September 2021 - Once daily dosing option now available to address KRAS G12C, a driver of tumour growth found ...
Posted by Michael Wonder on 02 Sep 2021
Natco Pharma (Canada) announces the launch of Nat-Lenalidomide capsules, the first generic alternative to Revlimid
1 September 2021 - Nat-Lenalidomide expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to ...
Posted by Michael Wonder on 25 Aug 2021
Health Canada grants marketing authorisation for Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
24 August 2021 - Minjuvi is a new therapeutic option for eligible patients with DLBCL in Canada to address an ...
Posted by Michael Wonder on 26 Jul 2021
BeiGene announces approval in Canada of Brukinsa (zanubrutinib) for the treatment of patients with mantle cell lymphoma
26 July 2021 - Second approval for BTK inhibitor Brukinsa in Canada. ...
Posted by Michael Wonder on 21 Jul 2021
New treatment authorised and available for Canadians with HER2 positive breast cancer
20 July 2021 - Phesgo, a fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection combines two treatments into ...
Posted by Michael Wonder on 08 Jul 2021
Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukaemia
7 July 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for ...
Posted by Michael Wonder on 06 Jul 2021
Knight Therapeutics announces Health Canada approval for Nerlynx (neratinib) to treat HER2 positive metastatic breast cancer
6 July 2021 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) in combination with capecitabine for the ...
Posted by Michael Wonder on 29 Jun 2021
Medexus receives Notice of Compliance to commercialise Treosulfan in Canada
28 June 2021 - Medexus Pharmaceuticals today announced that it has received a Notice of Compliance from Health Canada to ...
Posted by Michael Wonder on 21 Jun 2021
Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in Canada specifically for patients with advanced RET driven lung and thyroid cancers
21 June 2021 - Conditional marketing authorisation based on data from LIBRETTO-001 Phase 1/2, the largest trial ever reported in patients ...
Posted by Michael Wonder on 02 Jun 2021
Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as the first and only immunotherapy treatment for previously untreated unresectable malignant pleural mesothelioma
2 June 2021 - First new systemic therapy in more than 15 years for cancer related to asbestos exposure. ...
Posted by Michael Wonder on 01 Jun 2021
Health Canada approves Abecma (idecabtagene vicleucel), the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma
31 May 2021 - Abecma is the first personalised cell therapy available to Canadian patients for the treatment of adults ...
Posted by Michael Wonder on 19 Apr 2021
Darzalex SC becomes the first and only Health Canada approved treatment for patients with newly diagnosed light chain amyloidosis, a rare disease
19 April 2021 - Darzalex SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher haematologic ...
Posted by Michael Wonder on 18 Mar 2021
Novartis' Kisqali (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
18 March 2021 - Kisqali is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key ...
Posted by Michael Wonder on 17 Mar 2021
Health Canada approves new indication for lung cancer treatment option Alunbrig
17 March 2021 - First-line indication offers Canadians with advanced lung cancer new treatment options. ...
Posted by Michael Wonder on 16 Mar 2021
Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer
16 March 2021 - New approval provides Canadian patients with HER2 positive early breast cancer a proven treatment regimen in a ...